Autolus Therapeutics (NASDAQ:AUTL) Rating Increased to Strong-Buy at Jefferies Financial Group

Jefferies Financial Group upgraded shares of Autolus Therapeutics (NASDAQ:AUTL) to a strong-buy rating in a research report sent to investors on Monday,Zacks.com reports.

Several other analysts also recently commented on the stock. Mizuho reduced their target price on shares of Autolus Therapeutics from $12.00 to $10.00 and set an “outperform” rating for the company in a report on Tuesday, March 31st. HC Wainwright began coverage on shares of Autolus Therapeutics in a report on Tuesday, February 17th. They set a “buy” rating and a $9.00 target price for the company. Zacks Research raised shares of Autolus Therapeutics from a “strong sell” rating to a “hold” rating in a report on Friday, March 13th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Autolus Therapeutics in a report on Wednesday, January 21st. Finally, Needham & Company LLC restated a “buy” rating and issued a $10.00 price target on shares of Autolus Therapeutics in a research note on Thursday, April 9th. Two investment analysts have rated the stock with a Strong Buy rating, five have given a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $8.50.

Autolus Therapeutics Trading Down 1.3%

Shares of NASDAQ AUTL opened at $1.58 on Monday. Autolus Therapeutics has a 12 month low of $1.15 and a 12 month high of $2.70. The stock has a 50 day moving average of $1.50 and a 200-day moving average of $1.52. The company has a market capitalization of $420.50 million, a P/E ratio of -1.46 and a beta of 2.04.

Autolus Therapeutics (NASDAQ:AUTL) last issued its earnings results on Friday, March 27th. The company reported ($0.34) EPS for the quarter, missing the consensus estimate of ($0.27) by ($0.07). The business had revenue of $24.29 million for the quarter, compared to the consensus estimate of $23.92 million. Autolus Therapeutics had a negative return on equity of 99.05% and a negative net margin of 381.40%. Analysts predict that Autolus Therapeutics will post -1.05 EPS for the current fiscal year.

Institutional Trading of Autolus Therapeutics

A number of institutional investors have recently bought and sold shares of AUTL. Mak Capital One LLC boosted its holdings in Autolus Therapeutics by 53.5% in the 3rd quarter. Mak Capital One LLC now owns 26,017,616 shares of the company’s stock valued at $42,409,000 after purchasing an additional 9,062,518 shares during the period. Schroder Investment Management Group boosted its holdings in Autolus Therapeutics by 133.7% in the 3rd quarter. Schroder Investment Management Group now owns 8,433,253 shares of the company’s stock valued at $13,409,000 after purchasing an additional 4,824,763 shares during the period. Armistice Capital LLC lifted its position in shares of Autolus Therapeutics by 30.0% during the 3rd quarter. Armistice Capital LLC now owns 15,600,000 shares of the company’s stock valued at $25,428,000 after acquiring an additional 3,600,000 shares during the period. Bank of America Corp DE lifted its position in shares of Autolus Therapeutics by 108.1% during the 3rd quarter. Bank of America Corp DE now owns 2,029,593 shares of the company’s stock valued at $3,308,000 after acquiring an additional 1,054,458 shares during the period. Finally, Millennium Management LLC bought a new stake in shares of Autolus Therapeutics during the 3rd quarter valued at $639,000. Institutional investors own 72.83% of the company’s stock.

Autolus Therapeutics Company Profile

Autolus Therapeutics is a clinical-stage biopharmaceutical company specializing in the development of next-generation, programmed T cell therapies for the treatment of cancer. The company leverages proprietary technologies to engineer autologous T cells that target and eradicate tumor cells, with the aim of improving safety, efficacy and durability over existing cell therapies. Its R&D platform integrates antigen receptor design, gene editing and manufacturing optimization to generate candidates tailored for specific hematologic malignancies and solid tumor indications.

The company’s leading pipeline candidates include AUTO1, an optimized CD19-targeted CAR-T therapy for relapsed or refractory acute lymphoblastic leukemia, and AUTO3, a dual-targeted CD19/22 CAR-T program in development for diffuse large B-cell lymphoma.